LACK OF PROTECTION WITH REGARDS TO ANTIDEPRESSANTS AND CHILDREN – (10-20-04)



Failing the Public Health — Rofecoxib, Merck, and the FDA

By now everyone has heard that Merck pulled it’s blockbuster drug from the market. Not a big surprise, since it was mentioned here at least 3 years ago (October 2001, Research Updates) that there were cardiac issues with the selective COX-2 inhibitors. There was clearly a failure of the FDA to protect the public in this situation. But we have also recently seen the same lack of protection with regards to antidepressants and children. It is the almighty dollar that rules here, but the general public still believes that the FDA is really out there with our best interests at heart. So, they pull ephedra, possibly linked to a handful of deaths when used INAPPROPRIATELY, but take years to pull off drugs, used APPROPRIATELY, off the market.

NEJM — Failing the Public Health — Rofecoxib, Merck, and the FDA

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Drug Research
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”